Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
LDLR- |
RCV000238507 | SCV000295483 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2016-03-25 | criteria provided, single submitter | literature only | |
Ambry Genetics | RCV004020967 | SCV003976995 | likely pathogenic | Cardiovascular phenotype | 2023-06-08 | criteria provided, single submitter | clinical testing | The c.1525A>G (p.K509E) alteration is located in exon 10 (coding exon 10) of the LDLR gene. This alteration results from a A to G substitution at nucleotide position 1525, causing the lysine (K) at amino acid position 509 to be replaced by a glutamic acid (E). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been reported in several individuals with a clinical diagnosis or suspicious of familial hypercholesterolemia (Fouchier, 2001; Pek, 2018; Cui, 2019; Yang, 2019; Lee, 2019; Sustar, 2022). This amino acid position is not well conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. |
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, |
RCV000238507 | SCV000606450 | pathogenic | Hypercholesterolemia, familial, 1 | no assertion criteria provided | research |